Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
5.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.2K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

7.2K
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
7.2K
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

3.1K
3.1K
Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

T cell engagers: expanding horizons in oncology and beyond.

British journal of cancer·2025
Same author

The implications of oncolytic viruses targeting fibroblasts in enhancing the antitumoural immune response.

Heliyon·2024
Same author

Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells.

Journal for immunotherapy of cancer·2024
Same author

AAV production in stable packaging cells requires expression of adenovirus 22/33K protein to allow episomal amplification of integrated rep/cap genes.

Scientific reports·2023
Same author

Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?

Journal for immunotherapy of cancer·2023
Same author

Self-attenuating adenovirus enables production of recombinant adeno-associated virus for high manufacturing yield without contamination.

Nature communications·2022

Related Experiment Video

Updated: Mar 27, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K

Oncolytic viruses: finally delivering.

Leonard W Seymour1, Kerry D Fisher1

  • 1Department Oncology, University of Oxford, Oxford OX3 7DQ, UK.

British Journal of Cancer
|January 15, 2016
PubMed
Summary
This summary is machine-generated.

Oncolytic viruses offer targeted cancer therapy by amplifying within tumors, reducing side effects. They also enhance immune response and deliver targeted therapeutics, improving cancer treatment outcomes.

More Related Videos

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

10.0K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.6K

Related Experiment Videos

Last Updated: Mar 27, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

10.4K
Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses
06:13

Handling of the Cotton Rat in Studies for the Pre-clinical Evaluation of Oncolytic Viruses

Published on: November 24, 2014

10.0K
Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy
08:51

Genome-wide RNAi Screening to Identify Host Factors That Modulate Oncolytic Virus Therapy

Published on: April 3, 2018

9.6K

Area of Science:

  • Virology
  • Genetic Engineering
  • Pharmacology

Background:

  • Oncolytic viruses represent a versatile platform for developing molecularly targeted anticancer agents.
  • Traditional chemotherapy exposes normal tissues, limiting the therapeutic index.

Purpose of the Study:

  • To highlight the advantages of oncolytic viruses as anticancer agents.
  • To explore their potential in cancer treatment.

Main Methods:

  • The study discusses the inherent properties and mechanisms of oncolytic viruses.
  • It reviews their application in designing targeted anticancer therapies.

Main Results:

  • Oncolytic viruses amplify within tumors, maximizing therapeutic index and minimizing exposure to normal tissues.
  • Their cell-killing mechanisms reduce drug resistance, and lysis induces an anti-cancer immune response.
  • Tumor-selective expression of biologics offers potent, cost-effective targeted therapeutics.

Conclusions:

  • Oncolytic viruses provide a promising therapeutic strategy with multiple advantages over conventional treatments.
  • Further development can lead to potent and cost-effective targeted cancer therapies.